From Structure to Selectivity: Integrating CADD and AIDD in Rational Medicinal Chemistry Strategies for DYRK1A...

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Dual specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a CMGC kinase family member involved in numerous cellular processes.
• DYRK1A dysregulation is linked to Alzheimer's disease, Down syndrome, cancer, and diabetes.
• Current DYRK1A inhibitors lack selectivity due to conserved ATP-binding pockets in related kinases.

Purpose of the Study:

• To review recent advances in discovering selective DYRK1A inhibitors.
• To highlight the role of computational and AI-driven approaches in drug design.
• To discuss strategies for overcoming selectivity and pharmacokinetic limitations of DYRK1A inhibitors.

Main Methods:

• Computer-aided drug design (CADD).
• Artificial intelligence-driven drug design (AIDD).
• Rational drug design strategies.
• Structure-guided optimization.

Main Results:

• CADD and AIDD have facilitated the discovery of novel small-molecule DYRK1A inhibitors.
• These advanced methods improve inhibitor potency, selectivity, and drug-like properties.
• Expanded chemical space and new design paradigms for DYRK1A inhibitors have been achieved.

Conclusions:

• Computational and AI-driven drug design are crucial for developing selective DYRK1A inhibitors.
• These approaches offer solutions to the challenges in translating DYRK1A inhibitors to clinical use.
• Future DYRK1A-focused drug discovery will benefit significantly from CADD and AIDD methodologies.